Kirby McInerney LLP is investigating potential claims against Northwest
Biotherapeutics, Inc. (“Northwest Bio” or the “Company”) (Nasdaq:NWBO)
concerning whether the Company and its executives violated their
fiduciary duties.
On June 19, 2014 shares of the Company fell during intraday trading
$2.06 or 22.97% to trade at $6.91 after a report featured on
TheStreet.com stated, “The prestigious MD Anderson Cancer Center issued
a stern rebuke to Northwest Biotherapeutics (NWBO) for making
promotional, unjustified claims about results from an ongoing clinical
trial of an experimental cancer vaccine known as DCVax-Direct.” MD
Anderson Cancer Center is running the DCVax-Direct clinical trial with
funding from Northwest Biotherapeutics. According to the report,
investigators at MD Anderson, one of several sites conducting the study,
have not yet been able to analyze data collected because patients are
still being enrolled and treated in the study.
If you are a Northwest Bio stockholder and have information that could
assist in this investigation, please contact J. Brandon Walker, Esq. by
email at bwalker@kmllp.com, or
telephone at (212) 699-1145, Melissa Fortunato, Esq. by email at mfortunato@kmllp.com,
or telephone at (212) 699-1141, toll free at (888) 529-4787, or by filling
out this contact form. There is no cost or obligation to you.
Kirby McInerney LLP is a New York-based law firm concentrating in
securities, stockholder, whistleblower, antitrust and consumer
litigation. For additional information, please go to www.kmllp.com.
Copyright Business Wire 2014